Morgan Stanley notes that the firm’s AlphaWise team has updated its model on Tandem Diabetes projected pump shipments based on app download data and points out that the latest data suggests about 17% new patient shipments in Q3 based on mid-September data, which compares to Street expectations of 12% growth. At typical mix, that roughly 5% patient beat would add about 1% to group organic sales growth for the quarter, says the analyst, who has an Equal Weight rating and $45 price target on Tandem shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- TJX downgraded, Crocs upgraded: Wall Street’s top analyst calls
- Tandem Diabetes initiated with an Equal Weight at Morgan Stanley
- Street analysts say diabetes stocks âoverreactingâ to Lilly GLP-1 study results
- Diabetes stock selloff on Lilly Surmount-1 results overdone, says Citi
- Lake Street says Tandem should be bought on ‘overreaction’ to competitive fears